S&P 500   3,108.99 (+0.18%)
DOW   27,846.45 (+0.29%)
QQQ   201.71 (+0.00%)
CGC   18.56 (-8.53%)
BABA   184.96 (+0.05%)
GE   11.66 (+1.13%)
T   37.81 (+0.56%)
ACB   2.85 (-8.65%)
F   8.79 (+0.92%)
PRI   130.97 (+0.40%)
BAC   33.20 (+1.10%)
DIS   147.17 (+0.18%)
S&P 500   3,108.99 (+0.18%)
DOW   27,846.45 (+0.29%)
QQQ   201.71 (+0.00%)
CGC   18.56 (-8.53%)
BABA   184.96 (+0.05%)
GE   11.66 (+1.13%)
T   37.81 (+0.56%)
ACB   2.85 (-8.65%)
F   8.79 (+0.92%)
PRI   130.97 (+0.40%)
BAC   33.20 (+1.10%)
DIS   147.17 (+0.18%)
S&P 500   3,108.99 (+0.18%)
DOW   27,846.45 (+0.29%)
QQQ   201.71 (+0.00%)
CGC   18.56 (-8.53%)
BABA   184.96 (+0.05%)
GE   11.66 (+1.13%)
T   37.81 (+0.56%)
ACB   2.85 (-8.65%)
F   8.79 (+0.92%)
PRI   130.97 (+0.40%)
BAC   33.20 (+1.10%)
DIS   147.17 (+0.18%)
S&P 500   3,108.99 (+0.18%)
DOW   27,846.45 (+0.29%)
QQQ   201.71 (+0.00%)
CGC   18.56 (-8.53%)
BABA   184.96 (+0.05%)
GE   11.66 (+1.13%)
T   37.81 (+0.56%)
ACB   2.85 (-8.65%)
F   8.79 (+0.92%)
PRI   130.97 (+0.40%)
BAC   33.20 (+1.10%)
DIS   147.17 (+0.18%)
Log in

RAPT Therapeutics Stock Price, Forecast & Analysis (NASDAQ:RAPT)

$20.30
-0.40 (-1.93 %)
(As of 11/22/2019 10:20 AM ET)
Today's Range
$20.30
Now: $20.30
$20.60
50-Day Range N/A
52-Week Range
$11.85
Now: $20.30
$42.00
Volume35 shs
Average Volume117,834 shs
Market Capitalization$431.98 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RAPT
CUSIPN/A
CIKN/A
Phone650-489-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees64
Market Cap$431.98 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RAPT News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.


RAPT Therapeutics (NASDAQ:RAPT) Frequently Asked Questions

What is RAPT Therapeutics' stock symbol?

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

Has RAPT Therapeutics been receiving favorable news coverage?

News headlines about RAPT stock have been trending very negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. RAPT Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for RAPT Therapeutics.

Who are some of RAPT Therapeutics' key competitors?

What other stocks do shareholders of RAPT Therapeutics own?

Who are RAPT Therapeutics' key executives?

RAPT Therapeutics' management team includes the folowing people:
  • Dr. Brian Russell Wong, CEO, Pres & Director (Age 47)
  • Mr. Eric J. Hall CFA, Interim CFO & Sec. (Age 64)
  • Steve Young Ph.D., VP of Technology
  • Dr. Dirk G. Brockstedt Ph.D., Chief Scientific Officer (Age 50)
  • Ms. Erin Campany, VP of HR (Age 52)

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an initial public offering on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO.

When does RAPT Therapeutics' quiet period expire?

RAPT Therapeutics' quiet period expires on Tuesday, December 10th. RAPT Therapeutics had issued 3,000,000 shares in its initial public offering on October 31st. The total size of the offering was $36,000,000 based on an initial share price of $12.00. During RAPT Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is RAPT Therapeutics' stock price today?

One share of RAPT stock can currently be purchased for approximately $20.30.

How big of a company is RAPT Therapeutics?

RAPT Therapeutics has a market capitalization of $431.98 million. RAPT Therapeutics employs 64 workers across the globe.View Additional Information About RAPT Therapeutics.

What is RAPT Therapeutics' official website?

The official website for RAPT Therapeutics is http://www.rapt.com/.

How can I contact RAPT Therapeutics?

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-489-9000 or via email at [email protected]


MarketBeat Community Rating for RAPT Therapeutics (NASDAQ RAPT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  5
MarketBeat's community ratings are surveys of what our community members think about RAPT Therapeutics and other stocks. Vote "Outperform" if you believe RAPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RAPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel